97 M&A Deals in Four Days: Q2 Opens With a Corporate Buying Spree

Ninety-seven M&A transactions in four days. Over $36 billion in disclosed deal value. That is how Q2 2026 began — not with a trickle of tentative bids, but with a wall of signed agreements, completed acquisitions, and billion-dollar handshakes.

The pace is striking, but the breadth is what makes this week unusual. This was not a single sector catching fire. Pharma giants spent nearly $12 billion acquiring pipeline assets. A building materials company closed a $2.25 billion deal. A coffee empire was formally born. And across Europe, mid-market M&A played out in languages from Italian to French to Spanish, with deal after deal involving PE-backed exits and bolt-on acquisitions.

Here is what the data tells us about where acquirers are putting their money — and why.

Pharma Led on Value, but Not on Volume

If you ranked the week by dollars deployed, pharma dominated. Eli Lilly's $6.3 billion acquisition of Centessa Pharmaceuticals was the largest confirmed deal by a strategic buyer, adding a sleep disorder pipeline that Lilly clearly decided was cheaper to buy than build. Hours earlier, Biogen closed its $5.6 billion purchase of Apellis Pharmaceuticals, expanding into immunology and rare diseases.

These are not exploratory conversations. Both deals are completed. Combined, two pharma acquisitions accounted for nearly $12 billion — a third of all disclosed M&A value in the dataset.

Smaller pharma deals added texture. Cyclerion Therapeutics merged with Korsana Biosciences through a $380 million financing package to advance an Alzheimer's pipeline. Axsome Therapeutics acquired a PDE10A inhibitor targeting schizophrenia. CapVest completed its majority acquisition of STADA Arzneimittel, one of Europe's largest generic pharma companies.

The pattern is clear: big pharma is buying late-stage clinical assets rather than developing them in-house. The premium for speed is real.

The Deals That Defined Each Sector

Beyond pharma, each sector had its own headline-grabbing transaction.

In industrials, QXO closed its $2.25 billion acquisition of Kodiak Building Partners, a clear play on building materials distribution consolidation. DuPont divested its aramids business to Arclin for $1.8 billion, continuing its portfolio reshaping. Halliburton acquired Sekal to bring drilling automation in-house.

In food and beverage, Keurig Dr Pepper completed its acquisition of JDE Peet's, creating what is now arguably the world's largest pure-play coffee company. Clorox completed its purchase of GOJO Industries, the maker of Purell, expanding its hygiene brand footprint. McCormick's combination with Unilever Foods was another mega-deal that reshaped the consumer staples map.

In technology, SAP acquired Reltio to feed external data into its AI agent strategy. Autodesk bought Rhumbix for real-time construction site data. Franklin Templeton moved to acquire 250 Digital, a CoinFund spinoff, in a crypto expansion push. These are targeted capability acquisitions — each buyer filling a specific gap in their product or data stack.

April 1 Was the Busiest Day

The daily distribution tells its own story. March 30 was quiet with just 2 announced deals. March 31 brought 34. Then April 1 — the first business day of Q2 — hit 41 M&A announcements in a single day, the kind of volume that suggests deal pipelines were deliberately timed for the quarter's opening.

April 2 logged 20 deals by the time we tracked them, and the day was not over. The clustering around the Q2 start is not coincidental: it reflects a pattern where boards and advisors line up closings for the turn of a new quarter, giving clean financial reporting periods.

Europe's Mid-Market Is Buzzing

A notable feature of this week's M&A data: the volume of mid-market deals in continental Europe. Italy alone produced several notable transactions — Clessidra PE acquiring Sopran Ciodue in fire safety services, Angelini buying a majority stake in the Arnaldo Caprai winery, and CareHub (backed by Quadrivio) completing three acquisitions in healthcare services.

France saw L'Oréal finalize its acquisition of Kering Beauté, GEODIS acquire transport group Malherbe, and several smaller roll-ups. Spain contributed too, with Movento acquiring Auto Beltrán and Alantra selling its stake in Access Capital Partners for €115 million.

The European mid-market story is one of PE firms executing buy-and-build strategies and exiting mature positions — not the splashy auctions that grab headlines, but the steady assembly of sector-focused platforms.

The Fitness Mega-Merger Nobody Expected

Buried in a week of pharma billions and industrial divestitures was one deal that deserves attention for sheer ambition: the $7.5 billion merger between Playlist (parent of ClassPass and Mindbody) and EGYM. That valuation puts a fitness and wellness technology company on par with mid-cap pharma. The deal combines consumer-facing booking platforms with gym equipment technology — a bet that the gym industry's digital infrastructure will consolidate under one roof.

On the financial side, Apollo is reportedly nearing a $10 billion acquisition of KKR's Atlantic Aviation, which would be the largest single deal in this dataset. That transaction is not yet closed, but its scale signals continued appetite among PE firms for infrastructure-adjacent assets with stable cash flows.

Wealth Management: The Quiet Consolidation

Savant Wealth Management added $7 billion in assets through two RIA acquisitions. Composition Wealth merged with $900 million Edgewater Wealth. Cetera Financial Group acquired Matkovic Financial Group. Callan Family Office acquired Clarity Family Offices. Carlyle took a majority stake in MAI Capital Management at a $2.8 billion-plus valuation.

Five wealth management deals in four days. The RIA rollup trend that has been building for years is not slowing down — if anything, the deals are getting larger and the acquirers more aggressive. PE firms like Carlyle entering at multi-billion dollar valuations suggest this market still has room to consolidate.

What This Tells Us About Q2

Ninety-seven M&A deals in the opening days of a new quarter is a signal of confidence — or urgency. After a Q1 that saw record IPO filings and fundraising sprints, Q2 appears to be the quarter where those dry-powder commitments turn into signed term sheets.

Three patterns stand out. First, pharma M&A is being driven by pipeline urgency, not opportunism. Companies like Lilly and Biogen are paying premium prices for late-stage assets because the cost of delay exceeds the cost of overpaying. Second, European mid-market M&A is in a sustained boom, fueled by PE exits and buy-and-build strategies that now span a dozen countries. Third, the wealth management rollup is accelerating into its own asset class — with PE-scale capital now chasing what used to be a cottage industry.

If the rest of Q2 keeps this pace, 2026 will be remembered as the year M&A went from recovery to full sprint.